High CD3 and CD8 mRNA expression in early‐stage breast cancer patients is of prognostic value for decreased risk of relapse and, in the future, could potentially be of importance in deciding the most appropriate therapeutic strategy in light of the recent immune‐related treatment developments. The gene discussed is CD8A; the disease is breast carcinoma.